FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040549875> ?p ?o ?g. }

• W2040549875 endingPage "1824" @default.
• W2040549875 startingPage "1822" @default.
• W2040549875 abstract "No AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Nov 2004CONTROVERSIES IN PROSTATE CANCER SCREENING ALANA M. MURPHY, JAMES M. McKIERNAN, and CARL A. OLSSON ALANA M. MURPHYALANA M. MURPHY More articles by this author , JAMES M. McKIERNANJAMES M. McKIERNAN Financial interest and/or other relationship with Novartis Oncology and Aventis Oncology More articles by this author , and CARL A. OLSSONCARL A. OLSSON More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000140500.65341.9aAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Prostate cancer is the most common cancer in men and the second most common cause of cancer death in men, and yet controversy continues to surround the practice of prostate cancer screening. Despite recent studies that have cast doubt over the true efficacy of breast cancer screening programs, the National Cancer Institute continues to support breast cancer screening and it has withheld endorsement of widespread prostate cancer screening. Criticisms of prostate cancer screening include the financial burden of screening, the morbidity of prostate biopsy, the low positive predictive value of screening, the over treatment of an indolent disease and the lack of evidence demonstrating a mortality benefit due to screening. Materials and Methods: We formulated a comprehensive discussion addressing the criticisms of prostate cancer screening. Results: In an effort to highlight the importance of prostate cancer screening we noted how concerns regarding cost, morbidity and low positive predictive value are common to widely accepted screening programs for other common malignancies. We also draw attention to the danger of abandoning prostate cancer screening, a practice that is called into question by watchful waiting series and Markov modeling of prostate cancer treatment. Finally, we observed how the implementation of prostate cancer screening in the United States has led to the phenomenon of stage migration and paralleled the decrease in the prostate cancer mortality rate. Conclusions: The prostate specific antigen era has brought great promise for improving the prognosis of prostate cancer. We must continue to seek support for widespread prostate cancer screening. References 1 : Cancer Statistics, 2003. CA Cancer J Clin2003; 53: 5. Google Scholar 2 Projections of the Total Resident Population by 5-Year Age Groups, and Sex With Special Age Categories: Middle Serves, 2001 to 2005. Available at http://www.census.gov/population/projections/nation/summary/np-t3-b.txt. Accessed December 1, 2003. Google Scholar 3 E. Arlas, Smith, B.L.: Deaths: Preliminary Data for 2001. National Vital Statistics Reports, vol. 51, No. 5, March 14, 2003. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_05.pdf. Accessed December 1, 2003 Google Scholar 4 : Current results of the breast cancer screening randomized trial: the health insurance plan (HIP) of greater New York study. In: Screening for Breast Cancer. The Health Insurance Plan Project and Its Sequelae, 1963–1983. Baltimore: The Johns Hopkins University Press1988: 3. Google Scholar 5 : The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med2002; 137: 305. Google Scholar 6 : The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer1997; 80: 1852. Google Scholar 7 : An economic rationale for prostate cancer screening. Urology1994; 44: 795. Google Scholar 8 : Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology2002; 60: 826. Google Scholar 9 : Colonoscopy: a prospective report of complications. J Clin Gastroenterol1992; 15: 347. Google Scholar 10 : Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol2004; 171: 1089. Link, Google Scholar 11 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar 12 : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med2002; 347: 781. Google Scholar 13 : A Markov model of the natural history of prostate cancer. J Clin Epidemiol1994; 47: 3. Google Scholar 14 : Determining sensitivity of mammography from screening data, cancer incidence, and receiver-operating characteristic curve parameters. Med Decis Making2002; 22: 228. Google Scholar 15 : Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA1993; 270: 948. Google Scholar 16 : European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer1995; 76: 129. Google Scholar 17 : Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology2002; 60: 1034. Google Scholar 18 : Cancer statistics, 1993. CA Cancer J Clin1993; 43: 7. Google Scholar 19 : Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate2004; 59: 311. Google Scholar 20 : Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology2001; 58: 417. Google Scholar From the Department of Urology, Columbia University Medical Center, New York, New York© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byLatini D, Hart S, Knight S, Cowan J, Ross P, DuChane J and Carroll P (2018) The Relationship Between Anxiety and Time to Treatment for Patients With Prostate Cancer on SurveillanceJournal of Urology, VOL. 178, NO. 3, (826-832), Online publication date: 1-Sep-2007.PEYROMAURE M, DEBRÉ B, MAO K, ZHANG G, WANG Y, SUN Z, XU D, JIANG J and SUN Y (2018) MANAGEMENT OF PROSTATE CANCER IN CHINA: A MULTICENTER REPORT OF 6 INSTITUTIONSJournal of Urology, VOL. 174, NO. 5, (1794-1797), Online publication date: 1-Nov-2005. Volume 172Issue 5November 2004Page: 1822-1824 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsprostatic neoplasmsprostateprostate-specific antigenmass screeningMetricsAuthor Information ALANA M. MURPHY More articles by this author JAMES M. McKIERNAN Financial interest and/or other relationship with Novartis Oncology and Aventis Oncology More articles by this author CARL A. OLSSON More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2040549875 created "2016-06-24" @default.
• W2040549875 creator A5060409090 @default.
• W2040549875 creator A5068200379 @default.
• W2040549875 creator A5083458032 @default.
• W2040549875 date "2004-11-01" @default.
• W2040549875 modified "2023-09-30" @default.
• W2040549875 title "CONTROVERSIES IN PROSTATE CANCER SCREENING" @default.
• W2040549875 cites W1979256714 @default.
• W2040549875 cites W2043898347 @default.
• W2040549875 cites W2050465965 @default.
• W2040549875 cites W2051834074 @default.
• W2040549875 cites W2054128532 @default.
• W2040549875 cites W2070718488 @default.
• W2040549875 cites W2079907181 @default.
• W2040549875 cites W2080825275 @default.
• W2040549875 cites W2107937173 @default.
• W2040549875 cites W2109694492 @default.
• W2040549875 cites W2163350232 @default.
• W2040549875 cites W2163956404 @default.
• W2040549875 cites W4231335172 @default.
• W2040549875 cites W4248869731 @default.
• W2040549875 cites W4254912730 @default.
• W2040549875 cites W4255769636 @default.
• W2040549875 doi "https://doi.org/10.1097/01.ju.0000140500.65341.9a" @default.
• W2040549875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15540729" @default.
• W2040549875 hasPublicationYear "2004" @default.
• W2040549875 type Work @default.
• W2040549875 sameAs 2040549875 @default.
• W2040549875 citedByCount "32" @default.
• W2040549875 countsByYear W20405498752012 @default.
• W2040549875 countsByYear W20405498752013 @default.
• W2040549875 countsByYear W20405498752014 @default.
• W2040549875 countsByYear W20405498752015 @default.
• W2040549875 countsByYear W20405498752016 @default.
• W2040549875 countsByYear W20405498752017 @default.
• W2040549875 countsByYear W20405498752018 @default.
• W2040549875 countsByYear W20405498752020 @default.
• W2040549875 crossrefType "journal-article" @default.
• W2040549875 hasAuthorship W2040549875A5060409090 @default.
• W2040549875 hasAuthorship W2040549875A5068200379 @default.
• W2040549875 hasAuthorship W2040549875A5083458032 @default.
• W2040549875 hasConcept C121608353 @default.
• W2040549875 hasConcept C126322002 @default.
• W2040549875 hasConcept C143998085 @default.
• W2040549875 hasConcept C2775941076 @default.
• W2040549875 hasConcept C2776235491 @default.
• W2040549875 hasConcept C2779134260 @default.
• W2040549875 hasConcept C2780192828 @default.
• W2040549875 hasConcept C2781406297 @default.
• W2040549875 hasConcept C29456083 @default.
• W2040549875 hasConcept C71924100 @default.
• W2040549875 hasConceptScore W2040549875C121608353 @default.
• W2040549875 hasConceptScore W2040549875C126322002 @default.
• W2040549875 hasConceptScore W2040549875C143998085 @default.
• W2040549875 hasConceptScore W2040549875C2775941076 @default.
• W2040549875 hasConceptScore W2040549875C2776235491 @default.
• W2040549875 hasConceptScore W2040549875C2779134260 @default.
• W2040549875 hasConceptScore W2040549875C2780192828 @default.
• W2040549875 hasConceptScore W2040549875C2781406297 @default.
• W2040549875 hasConceptScore W2040549875C29456083 @default.
• W2040549875 hasConceptScore W2040549875C71924100 @default.
• W2040549875 hasIssue "5" @default.
• W2040549875 hasLocation W20405498751 @default.
• W2040549875 hasLocation W20405498752 @default.
• W2040549875 hasOpenAccess W2040549875 @default.
• W2040549875 hasPrimaryLocation W20405498751 @default.
• W2040549875 hasRelatedWork W161795195 @default.
• W2040549875 hasRelatedWork W1893851373 @default.
• W2040549875 hasRelatedWork W1899936169 @default.
• W2040549875 hasRelatedWork W1980245127 @default.
• W2040549875 hasRelatedWork W2106003470 @default.
• W2040549875 hasRelatedWork W2132373402 @default.
• W2040549875 hasRelatedWork W2165919621 @default.
• W2040549875 hasRelatedWork W2400504790 @default.
• W2040549875 hasRelatedWork W2429027331 @default.
• W2040549875 hasRelatedWork W2433835599 @default.
• W2040549875 hasVolume "172" @default.
• W2040549875 isParatext "false" @default.
• W2040549875 isRetracted "false" @default.
• W2040549875 magId "2040549875" @default.
• W2040549875 workType "article" @default.